Taxing Times for French Pharma - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Taxing Times for French Pharma
As the French Presidential campaign is underway, and politicians collaborate with businesses to revive a flagging economy, the pharmaceutical industry seizes the chance to lobby for equitable taxation to give the sector a much-needed boost.


Pharmaceutical Technology Europe


References

1. ARIIS, "Pétition d'ARIIS pour les présidentielles 2012" (ARIIS Website, 2012). http://www.ariis.fr, accessed 4 Apr., 2012.

2. A. Torsoli, "French Drugmakers Say Pricing Policy May Hamper Industry" (Bloomberg Website, 2012). http://mobile.bloomberg.com/, 4 Apr., 2012

3. The Pharma Letter, "Tax system for French drug firms to change" (The Pharma Letter Website, 2012). http://www.thepharmaletter.com/, accessed 4 Apr., 2012.

4. J. Cuadrado and C. Damiano, "French taxes specific to the pharmaceutical industry: cutting the health expenses or a different way of taxing the profitability of the pharmaceutical industry in France" in Tax on Transactions multi-jurisdictional guide (Practical Law Company Website, 2011). http://crossborder.practicallaw.com/, accessed 4 Apr., 2012.

5. Anon, "France loses AAA rating as euro governments downgraded" (BBC News Website, Jan. 12, 2012). http://www.bbc.co.uk/news/business-16552623, accessed 4 Apr., 2012.

6. H. Israël and C. Guionnet-Moalic, "France: How the Reform of the Tax Applicable to Pharmaceutical Product Turnover Will Affect Entities in this Field" (mondaq Website, 2005). http://www.mondaq.com/ accessed 4 Apr., 2012.

7. CSIS, Meeting of the Health Industries Strategic Advisory Board (Ministère de l'Économie, des Finances et de l'Industrie website, 2012). http://www.economie.gouv.fr, accessed 4 Apr., 2012.

8. Focus Reports, "France: The French Revolution" (Focus Reports Website, 2010). http://www.pharma.focusreports.net/, accessed 4 Apr., 2012.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology Europe,
Click here